evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

5 questions · 5 findings · 1 reviews · Headline outcomes only

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 5 · 100%

Mepolizumab subcutaneous (SC) vs placebo

Rate of clinically significant exacerbations requiring systemic corticosteroids · people with asthma

Mepolizumab subcutaneous (SC) leads to lower rate of clinically significant exacerbations requiring systemic… compared with placebo (high certainty).

1 finding from 1 review

Reslizumab intravenous (IV) vs placebo

Rate of clinically significant exacerbations requiring systemic corticosteroids · people with asthma

Reslizumab intravenous (IV) leads to lower rate of clinically significant exacerbations requiring systemic… compared with placebo (high certainty).

1 finding from 1 review

Reslizumab subcutaneous (SC) vs placebo

Rate of clinically significant exacerbations requiring systemic corticosteroids · people with asthma

Reslizumab subcutaneous (SC) showed no clear difference in rate of clinically significant exacerbations requiring systemic… compared with placebo (high certainty).

1 finding from 1 review

Benralizumab subcutaneous (SC) vs placebo

Rate of clinically significant exacerbations requiring systemic corticosteroids · people with asthma

Benralizumab subcutaneous (SC) leads to lower rate of clinically significant exacerbations requiring systemic… compared with placebo (high certainty).

1 finding from 1 review

Mepolizumab intravenous (IV) vs placebo

Rate of clinically significant exacerbations requiring systemic corticosteroids · people with asthma

Mepolizumab intravenous (IV) leads to lower rate of clinically significant exacerbations requiring systemic… compared with placebo (high certainty).

1 finding from 1 review